A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

161

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 20, 2027

Study Completion Date

December 27, 2027

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

BIOLOGICAL

Immune globulin (human) 10% solution for intravenous administration

Kedrion intravenous immunoglobulin (IVIg) 10%

All Listed Sponsors

lead

Kedrion S.p.A.

INDUSTRY